Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality

    Authors: Jesse Fajnzylber; James Regan; Kendyll Coxen; Heather Corry; Colline Wong; Alexandra Rosenthal; Daniel Worrall; Francoise Giguel; Alicja Piechocka-Trocha; Caroline Atyeo; Stephanie Fischinger; Andrew Chan; Keith Flaherty; Kathryn Hall; Michael Dougan; Edward Ryan; Elizabeth Gillespie; Rida Chishti; Yijia Li; Nikolaus Jilg; Dusan Hanidziar; Rebecca Baron; Lindsey Baden; Athe Tsibris; Katrina Armstrong; Galit Alter; Daniel Kuritzkes; Bruce Walker; Xu Yu; Jonathan Li

    doi:10.21203/rs.3.rs-43878/v1 Date: 2020-07-15 Source: ResearchSquare

    The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease MESHD 2019 (COVID-19). We quantified SARS-CoV-2 viral load from participants with a diverse range of COVID-19 severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection MESHD. SARS-CoV-2 plasma SERO RNA was detected in 27% of hospitalized participants and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, higher prevalence SERO of detectable SARS-CoV-2 plasma SERO viral load was associated with worse respiratory disease MESHD severity, lower absolute lymphocyte counts, and increased markers of inflammation MESHD, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma SERO viremia HP viremia MESHD, were associated with increased risk of mortality. SARS-CoV-2 viral load may aid in the risk stratification of patients with COVID-19 and its role in disease pathogenesis should be further explored.

    The antibody SERO response to the glycan α-Gal correlates with COVID-19 disease symptoms MESHD

    Authors: Jose Miguel Urra; Elisa Ferreras-Colino; Marinela Contreras; Carmen M Cabrera; Isabel G Fernandez de Mera; Margarita Villar; Christian Gortazar; Jose de la Fuente

    doi:10.1101/2020.07.14.201954 Date: 2020-07-14 Source: bioRxiv

    The coronavirus disease 19 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has affected millions of people worldwide. The characterization of the immunological mechanisms involved in disease symptomatology and protective response is important to advance in disease control and prevention. Humans evolved by losing the capacity to synthesize the glycan Gal1-3Gal{beta}1-(3)4GlcNAc-R (-Gal), which resulted in the development of a protective response against pathogenic viruses and other microorganisms containing this modification on membrane proteins mediated by anti--Gal IgM/IgG antibodies SERO produced in response to bacterial microbiota. In addition to anti--Gal antibody SERO-mediated pathogen opsonization, this glycan induces various immune mechanisms that have shown protection in animal models against infectious diseases MESHD without inflammatory responses. In this study, we hypothesized that the immune response to -Gal may contribute to the control of COVID-19. To address this hypothesis, we characterized the antibody SERO response to -Gal in patients at different stages of COVID-19 and in comparison with healthy control individuals. The results showed that while the inflammatory response and the anti-SARS-CoV-2 (Spike) IgG antibody SERO titers increased, reduction in anti--Gal IgE, IgM and IgG antibody SERO titers and alteration of anti--Gal antibody SERO isotype composition correlated with COVID-19 severity. The results suggested that the inhibition of the -Gal-induced immune response may translate into more aggressive viremia MESHD viremia HP and severe disease inflammatory symptoms. These results support the proposal of developing interventions such as probiotics based on commensal bacteria with -Gal epitopes to modify the microbiota and increase the -Gal-induced protective immune response and reduce the severity of COVID-19.

    Single-Cell RNA-seq Identifies Cell Subsets in Human Placenta That Highly Expresses Factors to Drive Pathogenesis of SARS-CoV-2 MESHD

    Authors: Nancy Ashray; Anshul Bhide; Priyanka Chakarborty; Stacy Colaco; Anuradha Mishra; Karisma Chhabria; Mohit Kumar Jolly; Deepak Modi

    id:10.20944/preprints202005.0195.v1 Date: 2020-05-11 Source: Preprints.org

    Infection by the Severe HP Acute Respiratory Syndrome-Coronavirus-2 MESHD (SARS-CoV-2) results in the novel coronavirus disease COVID-19, which has posed a serious threat globally. Infection of SARS-CoV-2 during pregnancy is associated with complications like preterm labor MESHD and premature rupture of membranes HP; a proportion of neonates born to the infected mothers are also positive for the virus. During pregnancy, the placental barrier protects the fetus from pathogens and ensures healthy development. However, whether or not SARS-CoV-2 can infect MESHD the placenta is unknown. Herein, utilizing single-cell RNA-seq data, we report that the SARS-CoV-2 binding receptor ACE2 and the S protein priming protease TMPRSS2 are co-expressed by a subset of syncytiotrophoblasts (STB) in the first trimester and extra villous trophoblasts (EVT) in the second trimester human placenta. The ACE2- and TMPRSS2-positive (ACE2+TMPRSS2+) placental subsets express mRNA for proteins involved in viral budding and replication. These cells also express mRNA for proteins that interact with SARS-CoV-2 structural and non-structural proteins in the host cells. We also discovered unique signatures of genes in ACE2+TMPRSS2+ STBs and EVTs. The ACE2+TMPRSS2+ STBs are highly differentiated cells and express genes involved mitochondrial metabolism and glucose transport. The second trimester ACE2+TMPRSS2+ EVTs are enriched for markers of endovascular trophoblasts. Further, both these subtypes abundantly expressed genes in Toll like receptor pathway, the second trimester EVTs (but not first trimester STBs) are also enriched for component of the JAK-STAT pathway that drive inflammation MESHD. To conclude, herein we uncovered the cellular targets for SARS-CoV-2 entry MESHD and show that these cells can potentially drive viremia HP viremia MESHD in the developing human placenta. Our results provide a basic framework towards understanding the paraphernalia involved in SARS-CoV-2 infections MESHD in pregnancy.

    The feasibility of convalescent plasma SERO therapy in severe COVID-19 patients: a pilot study

    Authors: Kai Duan; Bende Liu; Cesheng Li; Huajun Zhang; Ting Yu; Jieming Qu; Min Zhou; Li Chen; Shengli Meng; Yong Hu; Cheng Peng; Mingchao Yuan; Jinyan Huang; Zejun Wang; Jianhong Yu; Xiaoxiao Gao; Dan Wang; Xiaoqi Yu; Li Li; Jiayou Zhang; Xiao Wu; Bei Li; Yanping Yu; Wei Chen; Yan Peng; Yeqin Hu; Lianzhen Lin; Xuefei Liu; Shihe Huang; Zhijun Zhou; Lianghao Zhang; Yue Wang; Zhi Zhang; Kun Deng; Zhiwu Xia; Qin Gong; Wei Zhang; Xiaobei Zheng; Ying Liu; Huichuan Yang; Dongbo Zhou; Ding Yu; Jifeng Hou; Zhengli Shi; Saijuan Chen; Zhu Chen; Xin-xin Zhang; Xiaoming Yang

    doi:10.1101/2020.03.16.20036145 Date: 2020-03-23 Source: medRxiv

    Currently, there are no approved specific antiviral agents for 2019 novel coronavirus disease MESHD (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma SERO (CP) derived from recently recovered donors with the neutralizing antibody SERO titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody SERO increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65*109/L vs. 0.76*109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia HP viremia MESHD. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia HP viremia MESHD in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.